Recent Investment Analysts’ Ratings Changes for Dynavax Technologies (DVAX)

A number of firms have modified their ratings and price targets on shares of Dynavax Technologies (NASDAQ: DVAX) recently:

  • 5/13/2019 – Dynavax Technologies was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Dynavax Technologies discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Dynavax’s clinical development programs are based on immunostimulatory sequences which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. “
  • 5/9/2019 – Dynavax Technologies had its “outperform” rating reaffirmed by analysts at William Blair.
  • 5/7/2019 – Dynavax Technologies was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating.
  • 5/7/2019 – Dynavax Technologies was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Dynavax Technologies discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Dynavax’s clinical development programs are based on immunostimulatory sequences which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. “
  • 5/1/2019 – Dynavax Technologies was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating.
  • 4/15/2019 – Dynavax Technologies was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Dynavax Technologies discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Dynavax’s clinical development programs are based on immunostimulatory sequences which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. “
  • 4/9/2019 – Dynavax Technologies was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Dynavax Technologies discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Dynavax’s clinical development programs are based on immunostimulatory sequences which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. “
  • 4/3/2019 – Dynavax Technologies was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Dynavax Technologies discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Dynavax’s clinical development programs are based on immunostimulatory sequences which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. “
  • 4/1/2019 – Dynavax Technologies was upgraded by analysts at ValuEngine from a “sell” rating to a “hold” rating.
  • 3/28/2019 – Dynavax Technologies was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Dynavax Technologies discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Dynavax’s clinical development programs are based on immunostimulatory sequences which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. “
  • 3/21/2019 – Dynavax Technologies was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Dynavax Technologies discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Dynavax’s clinical development programs are based on immunostimulatory sequences which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. “

Shares of DVAX stock traded down $0.13 on Wednesday, reaching $6.63. 668,100 shares of the stock were exchanged, compared to its average volume of 1,069,532. The company has a market cap of $454.80 million, a P/E ratio of -2.60 and a beta of 0.60. Dynavax Technologies Co. has a one year low of $6.22 and a one year high of $19.50. The company has a quick ratio of 4.08, a current ratio of 5.27 and a debt-to-equity ratio of 4.88.

Dynavax Technologies (NASDAQ:DVAX) last released its earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.62) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.05. The company had revenue of $5.77 million during the quarter, compared to the consensus estimate of $5.95 million. Dynavax Technologies had a negative return on equity of 190.84% and a negative net margin of 1,156.11%. The firm’s quarterly revenue was up 3294.1% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.63) earnings per share. As a group, equities research analysts anticipate that Dynavax Technologies Co. will post -2.21 earnings per share for the current fiscal year.

In related news, SVP Robert Coffman sold 63,202 shares of Dynavax Technologies stock in a transaction on Thursday, February 28th. The stock was sold at an average price of $9.03, for a total transaction of $570,714.06. Following the completion of the sale, the senior vice president now directly owns 86,268 shares of the company’s stock, valued at $779,000.04. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Michael S. Ostrach sold 35,444 shares of Dynavax Technologies stock in a transaction on Thursday, February 28th. The stock was sold at an average price of $8.94, for a total value of $316,869.36. Following the sale, the insider now directly owns 121,581 shares of the company’s stock, valued at $1,086,934.14. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 119,411 shares of company stock valued at $1,075,091. 3.47% of the stock is currently owned by corporate insiders.

Several institutional investors have recently made changes to their positions in DVAX. JPMorgan Chase & Co. grew its position in Dynavax Technologies by 1.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 264,669 shares of the biopharmaceutical company’s stock valued at $3,282,000 after buying an additional 4,591 shares during the last quarter. MetLife Investment Advisors LLC grew its position in Dynavax Technologies by 55.5% in the 3rd quarter. MetLife Investment Advisors LLC now owns 44,609 shares of the biopharmaceutical company’s stock valued at $553,000 after buying an additional 15,919 shares during the last quarter. Vanguard Group Inc. grew its position in Dynavax Technologies by 1.0% in the 3rd quarter. Vanguard Group Inc. now owns 2,883,887 shares of the biopharmaceutical company’s stock valued at $35,759,000 after buying an additional 29,898 shares during the last quarter. Marshall Wace LLP purchased a new position in Dynavax Technologies in the 3rd quarter valued at $974,000. Finally, Vanguard Group Inc grew its position in Dynavax Technologies by 1.0% in the 3rd quarter. Vanguard Group Inc now owns 2,883,887 shares of the biopharmaceutical company’s stock valued at $35,759,000 after buying an additional 29,898 shares during the last quarter. 84.07% of the stock is owned by institutional investors and hedge funds.

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older.

Recommended Story: Gross Domestic Product (GDP)

Receive News & Ratings for Dynavax Technologies Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies Co and related companies with MarketBeat.com's FREE daily email newsletter.